Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Net Income (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Net Income readings, the most recent being $32860.0 for Q1 2026.

  • On a quarterly basis, Net Income rose 284.96% to $32860.0 in Q1 2026 year-over-year; TTM through Jan 2026 was -$85697.0, a 82.8% increase, with the full-year FY2025 number at -$100463.0, up 87.08% from a year prior.
  • Net Income hit $32860.0 in Q1 2026 for Pharma-Bio Serv, up from -$102.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $526242.0 in Q3 2023 to a low of -$309194.0 in Q3 2024.
  • Median Net Income over the past 5 years was $32860.0 (2026), compared with a mean of $86004.9.
  • Biggest five-year swings in Net Income: crashed 163.48% in 2024 and later soared 284.96% in 2026.
  • Pharma-Bio Serv's Net Income stood at $173379.0 in 2022, then crashed by 127.19% to -$47148.0 in 2023, then soared by 134.17% to $16111.0 in 2024, then plummeted by 100.63% to -$102.0 in 2025, then soared by 32315.69% to $32860.0 in 2026.
  • The last three reported values for Net Income were $32860.0 (Q1 2026), -$102.0 (Q4 2025), and -$213808.0 (Q3 2025) per Business Quant data.